Medication-Assisted Treatment (MAT)
Our national MAT initiative seeks to increase the use of acamprosate, naltrexone (both in oral and injectable form), buprenorphine and new medications as their proven benefits emerge — in combination with proven psychosocial interventions — in the treatment of substance use disorders where clinically appropriate.
How does Magellan’s program work?
- Focuses on patients who have been discharged from inpatient substance use treatment programs
- Targets individuals receiving outpatient case or disease management services
- Monitors the number of cases in which physicians are prescribing medications and follows member readmission rates
- Involves continual collaboration with Magellan’s health plan partners to help facilitate the incorporation of these medications into client formularies
- Advocates provider education on the importance of using appropriate medications when developing members’ substance use disorder treatment plans.